- Home
- LUMN vs LEXX Comparison
LUMN vs LEXX Comparison
Compare LUMN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUMN
- LEXX
- Stock Information
- Founded
- LUMN 1968
- LEXX 2004
- Country
- LUMN United States
- LEXX Canada
- Employees
- LUMN N/A
- LEXX N/A
- Industry
- LUMN Telecommunications Equipment
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- LUMN Telecommunications
- LEXX Health Care
- Exchange
- LUMN Nasdaq
- LEXX Nasdaq
- Market Cap
- LUMN N/A
- LEXX 23.3M
- IPO Year
- LUMN 1972
- LEXX N/A
- Fundamental
- Price
- LUMN $4.39
- LEXX $1.08
- Analyst Decision
- LUMN Hold
- LEXX Strong Buy
- Analyst Count
- LUMN 9
- LEXX 1
- Target Price
- LUMN $4.78
- LEXX $7.00
- AVG Volume (30 Days)
- LUMN 10.2M
- LEXX 107.1K
- Earning Date
- LUMN 05-01-2025
- LEXX 04-14-2025
- Dividend Yield
- LUMN N/A
- LEXX N/A
- EPS Growth
- LUMN N/A
- LEXX N/A
- EPS
- LUMN N/A
- LEXX N/A
- Revenue
- LUMN $13,000,000,000.00
- LEXX $525,923.00
- Revenue This Year
- LUMN N/A
- LEXX $30.72
- Revenue Next Year
- LUMN N/A
- LEXX $31.85
- P/E Ratio
- LUMN N/A
- LEXX N/A
- Revenue Growth
- LUMN N/A
- LEXX 29.95
- 52 Week Low
- LUMN $0.97
- LEXX $1.11
- 52 Week High
- LUMN $10.33
- LEXX $4.44
- Technical
- Relative Strength Index (RSI)
- LUMN 64.61
- LEXX 36.47
- Support Level
- LUMN $4.11
- LEXX $1.01
- Resistance Level
- LUMN $4.46
- LEXX $1.69
- Average True Range (ATR)
- LUMN 0.23
- LEXX 0.10
- MACD
- LUMN 0.15
- LEXX -0.02
- Stochastic Oscillator
- LUMN 94.74
- LEXX 10.29
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.